Efficacy and Safety of Cholecalciferol Supplementation in Vitamin D Deficient Subjects Based on Endocrine Society Clinical Practice GuidelinesChittari Venkata Harinarayan1*, Leena Appicatlaa2, Bangalore Arunachalam Nalini3 and Shalini Joshi3
- corresponding Author:
- Prof C.V.Harinarayan
Fortis Hospitals (opp IIM-B), Bannerughatta Road
Bangalore - 560 076, India
E-mail: [email protected]
Received Date: January 09, 2012; Accepted Date: February 13, 2012; Published Date: February 15, 2012
Citation: Harinarayan CV, Appicatlaa L, Nalini BA, Joshi S, et al. (2012) Efficacy and Safety of Cholecalciferol Supplementation in Vitamin D Deficient Subjects Based on Endocrine Society Clinical Practice Guidelines. Endocrinol Metabol Syndrome S4:004. doi: 10.4172/2161-1017.S4-004
Copyright: © 2012 Harinarayan CV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Hypovitaminosis is widely prevalent in India with limited data on vitamin D supplementation regimens.
Objective: We studied efficacy and safety of vitamin D supplementation as per the Endocrine Society Clinical
Practice Guidelines (ESCPG) in vitamin D deficient subjects.
Design: Fifty two healthy subjects had their serum albumin, creatinine, calcium, alkaline phosphatase, 25 OH
vitamin D (25OH D) and ntact PTH estimated at baseline, two and five months of supplementation. They were
supplemented with Cholecalciferol 9572 IU/day and elemental calcium 1 gm/day. At the end of the 2nd month, those
who attained vitamin D sufficiency were supplemented Cholecalciferol 3000 IU/day, and those still did not attain vitamin
D sufficiency with Cholecalciferol 5286 IU/day along with 1 gm elemental calcium and the later were reassessed after
Results: The mean ± SD of serum calcium, phosphorous, alkaline phosphatase were in the normal range at
baseline, 2 and 5 months of supplementation (P= NS). The baseline median (IQR-Interquartile range) of 25 OHD and
PTH was 6 (4-11) ng/ml and 19.6 (33-62) pg/ml respectively. At 2nd month there was threefold increase in 25 OHD
levels 19.6 (14.6-28.75) ng/ml and further 50% increase at 5th month of supplementation. PTH levels were suppressed
by 38 % at 2nd month and remained stable at 5th month. At end of 5th month, 46% had attained vitamin D sufficiency
and 27% of subjects were still vitamin D insufficient.
Conclusions: Vitamin D supplementation based on recent ESCPG even up to upper tolerable intake levels (UL)
along with elemental calcium of 1gm/day is safe and does not lead to hypercalcemia.